Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market [Seeking Alpha]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Seeking Alpha
ZVRA's valuation appears deeply discounted, with significant upside from EU expansion, pipeline assets Celiprolol and KP-1077, and a strong $200M cash position. FY26 is projected as the first year of true profitability, with analyst EPS estimates between $0.29 and $1.07 and revenue growth driven by MIPLYFFA. Even under pessimistic scenarios, ZVRA's risk/reward skews attractively, with 2030 per-share value estimates of $28–$42, representing a 25–36% CAGR from current levels. Catherine Delahaye/DigitalVision via Getty Images Introduction Zevra Therapeutics ( ZVRA ) announced Q3 FY25 earnings on November 5th, 2025, reporting a strong quarter with net revenues of $26.1 million ($22.4 million of which came from their primary revenue driver, MIPLYFFA). This represents a revenue increase of 605% over the same quarter last year This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of ZVRO either through stock ownership, options, or
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare ConferenceGlobeNewswire
- Zevra Therapeutics (NASDAQ:ZVRA) was given a new $26.00 price target on by analysts at HC Wainwright.MarketBeat
- Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)GlobeNewswire
- Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 1/7/26 - Form 4
- 12/17/25 - Form 8-K
- 12/9/25 - Form 4
- ZVRA's page on the SEC website